<div class="article">
	<h3>International Brief -- Glaxo Holdings PLC:
   Pretax Profit Climbs 13%
   At British Drug Company</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 09/21/90</li>
		</ul>
	</div>
	<p class="article-leader">Glaxo Holdings PLC, a major British pharmaceuticals
concern, reported a 13% rise in pretax profit for the year to
June 30, with strong sales throughout the company, including
its key Zantac anti-ulcer drug.
   Glaxo's pretax profit of #1.14 billion ($2.15 million), up
from #1.01 billion a year earlier, was ahead of market
expectations which ranged between #1.08 billion and #1.13
billion.</p>
	<div class="article-body"><p>Profit after tax, less minorities, or profit attributable
to shareholders, increased 15% to #793 million from #688
million a year earlier. Per-share earnings were up 15% to
53.1 pence from 46.2 pence.</p>
<p>Sales rose 11% to #2.85 billion from #2.57 billion, even
after exchange rate movements cut sales by #145 million,
Glaxo said.</p>
<p></p></div>
</div>
